TRIP Clinical Trial: Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson’s disease

Cognitive impairment and dementia are a top concern for people living with Parkinson’s disease (PD). The TRIP study explores a potential treatment for mild memory impairment with the overall aim of reducing dementia risk in Parkinson’s disease. This study is registered at:


Dana Pourzinal


Phone: (07) 3346 5028

I want to participate